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Introduction
Voltage-gated K + -channels of the Shaker family play an important role in governing cardiac excitability (Roden and George 1997; Snyders, 1999) . A variety of antiarrhythmic agents target
Shaker-based channels (Tamargo et al., 2004; Varro et al., 2004) , and such actions are believed to contribute to their actions in man. The cardiac transient outward current (I to ) subunits Kv1.4 and Kv4.2 differ in their sensitivity to the antiarrhythmic drug flecainide, with Kv4.2 being much more sensitive than Kv1.4. This difference has been used to probe the various contributions of Kv1.4 and Kv4.2 to native I to in the rat (Yeola and Snyders, 1997) . Kv1.5, the principal ionic current underlying human atrial ultra-rapid delayed rectifier current (I Kur ) (Wang et al., 1993; Feng et al., 1997 ) is a potentially interesting atrial-selective ionic target for drug therapy of atrial fibrillation (AF) (Nattel et al., 1999) . The dog counterpart, I Kur.d , appears to have a contribution from Kv3.1 subunits (Yue et al., 1996; Yue et al., 2000a) , although the importance of this contribution has recently been questioned (Fedida et al., 2003) . In previous work, we found I Kur.d to be sensitive to flecainide (Yue et al., 2000b) , unlike human I Kur , which appears resistant (Wang et al., 1995) . In preliminary studies, we observed corresponding differences in the flecainide sensitivity of Kv3.1 and Kv1.5 (Herrera et al., 2002) , reminiscent of the differences typically observed between Kv4.2 and Kv1.4. The present study was designed to characterize flecainide block of Kv3.1 and Kv1.5, and then to determine whether there is a common molecular basis for flecainide-sensitivity differences between Kv1.4 and Kv1.5 on one hand, and Kv3.1 and Kv4.2 on the other.
We began by constructing several chimeras of the Kv3.1 and Kv1.5 wild-type channels to identify important domains of flecainide block in these channels. This was followed by sitedirected mutagenesis of the identified domains to determine whether specific residues might This article has not been copyedited and formatted. The final version may differ from this version. modulate sensitivity of these channels to flecainide. The results of these studies pointed to a key role for the presence of leucine versus isoleucine at a specific amino acid location. Finally, a mathematical model was applied to assess the location and orientation of this amino acid in relation to key structures in the Kv3.1 channel molecule.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Molecular Biology. Wild-type (WT) dKv3.1 (GenBank #AF153198), hKv1.5 (GenBank #XM_006988, kindly provided by Dr. Barbara Wible) and rKv1.4 (GenBank #NM_012971, kindly provided by Dr. Barbara Wible), were cloned into a pSP64 (Promega, Madison, WI) and rKv4.2 (GenBank #S64320, kindly provided by Dr. Jeanne Nerbonne) into a pRC-CMV expression vector (Invitrogen Life Technologies, Carlsbad, CA) with identical restriction endonuclease sites flanking the clone in the polyclonal region for ligating the digest product into the target vector.
For chimera construction we performed a series of polymerase chain reactions (PCRs) with
Elongase Enzyme Mix (Invitrogen Life Technologies) and respective WTs as templates. For overlap extension of both products we used a third PCR and the products of each of the previous reactions as the template. The synthetic oligonucleotide primers used for the first reactions contained the ends of the chimera and the restriction endonuclease sites for cloning into the expression vector (Table 1 ). The complementary primer contained part of one clone and an overlap overhang for the overlap extension PCR. The third PCR employed the end primers to create a continuous string of nucleotides of the desired sequence. The final products and target vectors were digested with appropriate restriction endonucleases (Table 1) and ligated with Quick T4 DNA ligase (New England Biolabs, Beverley, MA).
For site-directed mutagenesis, PCR was applied, with a synthetic oligonucleotide primer containing the desired nucleotide to create the point mutation upon translation. Two complementary primers containing desired mutation and PCR primers flanking unique restriction enzyme sites enclosed the region of interest. Two parallel PCR reactions, each with a flanking primer and a primer containing the desired mutation, generated two DNA fragments with This article has not been copyedited and formatted. The final version may differ from this version. overlapping ends. After gel purification, both fragments were annealed in a third PCR using the two restriction site flanking primers, resulting in a fragment containing the desired mutation. The final PCR product was digested with the flanking restriction enzymes, gel-purified, and TOPO-TA cloned into the PCRII vector. All PCR-generated sequences were verified by double-stranded sequencing. After sequence confirmation, the mutant was released from PCRII at flanking restriction sites and ligated into pSP64 (or pRC-CMV) containing the coding region for the respective WT from which the segments enclosed by the restriction enzyme sites had been removed. (1000 U/L) (Invitrogen), streptomycin (100 mg/L) (Invitrogen), kanamycin (100 mg/L) and sodium pyruvate (275 mg/L) (Sigma) for 12 hours at 15°C.
5'-Capped polyadenylated cRNA was prepared for each construct with the SP6 mMessage mMachine in-vitro transcription kit (Ambion) after cDNA linearization. Xenopus oocytes were injected with ∼1-1.4 ng/oocyte of cRNA using a microinjector and stored for at least 12 hours in Barth's solution containing antibiotics and 5% horse serum at 15°C. Oocytes were placed in a recording/perfusion chamber and perfused at 0.5 mL/min with (mM): 5.0 KCl, 100 NaCl, This article has not been copyedited and formatted. The final version may differ from this version. Current-injecting electrode resistance averaged 1.5 MΩ. Voltage command pulses were generated with pClamp 6 software connected to a 12-bit Digidata 1200 analog-to-digital converter (Axon). A holding potential (HP) of -60 mV was used as in previous studies of native currents (Yue et al., 2000; Wang et al., 1995) . The effects of flecainide (Sigma) exposure were monitored with test pulses to +60 mV (in 10 mV steps). The inter-pulse interval was 10 seconds for all protocols and pulse length is indicated in figure insets. Recordings were low-pass filtered at 1 kHz. Data were analyzed with pClamp 6 (Axon Instruments) and are expressed as Modeller (Sali and Blundell, 1993) and on the RMS deviation between the atomic coordinates of the template relative to the model. Energy minimization was carried out on the four best models using Charmm (Brooks et al., 1983) . The overall structural quality of the generated models was confirmed by PROCHECK (Laskowski et al., 1993) . Structural features of flecainide were approximated using HyperChem 7.5 (Hyperchem, Gainesville, FL) and the AMBER force field (Weiner et al., 1984) .
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1A) . Overall, 50 µM flecainide significantly inhibited dKv3.1 current at all voltages positive to 0 mV, with a mean 58.9±3.9% reduction at +30 mV (Fig. 1B) . In contrast, the same concentration of flecainide had little apparent effect on Kv1.5 currents (Fig. 1C) , and mean Kv1.5 current amplitude was not significantly affected (Fig. 1D ). These observations indicate important differences between Kv1.5 and Kv3.1 in their sensitivity to the drug. Figure 2 shows the effects of the full range of drug concentrations on Kv3.1 and Kv1.5. Figure 2A illustrates the effects of increasing drug concentrations on current recorded upon stepping from -60 to +30 mV in single oocytes expressing each subunit. Flecainide appreciably decreased Kv3.1 current at 20 µM and produced near-total block of end-pulse current at 500 µM.
In contrast, Kv1.5 was minimally affected by 50 µM flecainide and 500 µM drug produced just over 50% inhibition. Figure 2B shows mean concentration-response data for flecainide inhibition For Kv1.5, the V ½ was -11.6±1.8 mV (slope factor 7.2±1.8 mV) before and -16.9±1.9 mV (slope factor 7.4±1.9 mV) after 500
The rapid decay of current in the presence of flecainide suggests open-channel blocking. Fig. 2A . Figure 3B shows corresponding data for Kv1. Table 2 unblock through the open state upon repolarization and carry significant current, thus slowing the apparent rate of deactivation. This process will be reflected in a slower time course of the tail current, resulting in tail current 'crossover' (Armstrong, 1971) . The tail-current time course was fitted by monoexponential relations (as shown by the solid lines fitted to the experimental data points shown in Figures 3C and D) , providing the mean data shown in Figure 3E . These results
show that the rate of current decay upon repolarisation was prolonged significantly in the presence of drug. Kv3.1 tail-current time constants increased from 54.8±2.7 ms (control) to This article has not been copyedited and formatted. The final version may differ from this version. Response of Kv3.1/Kv1.5 Chimeras to Flecainide. As an initial approach to analyzing the molecular determinants of the differential flecainide sensitivity of Kv3.1 and Kv1.5, we constructed chimeras between the two subunits. Two sets of reciprocal chimeras were constructed. Since we had already observed block of the wild-type channels in their open configuration we decided to concentrate on the pore to C-terminal region (see figure 3C , D and E). One set of chimeras involved the C-terminal distal to position Asn-436 in Kv3.1 and Asn-518 in Kv1.5. Figure 4A , top panels, show typical recordings before and after 50 µM flecainide in WT Kv3.1 and Kv1.5, whereas the middle panels show corresponding recordings from Kv3.1 subunits with their C-terminal replaced by those of Kv1.5 and Kv1.5 subunits with Kv3.1 Cterminal substitution. There was clearly no major change in sensitivity. We therefore interchanged longer segments of each subunit, involving the C-terminal distal to Met-414 in the Kv3.1 S6 segment and Lys-494 in the Kv1.5 S6. Figure 4A (bottom panels) show that flecainide sensitivity was somewhat decreased for Kv3.1 subunits containing the S6+C-terminal component of Kv1.5 and that sensitivity was increased for the corresponding Kv1.5 chimera. Figure are significantly different from their respective WTs and not different from each other. These results suggest that molecular motifs in S6 play a role in determining the flecainide affinity differences between Kv3.1 and Kv1.5. We next proceeded to address the potential role of specific amino acid residues in these drug affinity differences.
Effects of Mutating Candidate Amino Acids in Kv3.1 and Kv1.5 on Flecainide Sensitivity. The results described above suggest that flecainide produces open-channel block of both Kv3.1 and Kv1.5, with marked differences in affinity. We noted that similar differences in flecainide affinity had previously been reported for Kv1.4 (Yamagishi et al., 1995) , which like its Kv1 subfamily co-member Kv1.5 is flecainide-insensitive, and Kv4.2 (Caballero et al., 2003) , which is typically flecainide-sensitive. In addition, we noted that many of the amino acids that determine drug block of voltage-dependent K + -channels are situated in the S5-S6 linker region or in S6 (Yeola et al., 1996; Franqueza et al., 1997; Zhang et al., 1998; Caballero et al., 2002; Decher et al., 2004) . We therefore aligned and compared these portions of the sequences of rKv1.4, hKv1.5, dKv3.1 and rKv4.2 with one another. As shown in Fig. 5 , there was a large degree of homology among these subunits. At three positions (shown by boxes and symbols corresponding to their respective position in the channel protein), amino-acid residues corresponded for Kv1.4 and Kv1.5, on one hand, and for Kv3.1 and Kv4.2, on the other, but differed between the sensitive and insensitive subunits.
We therefore considered these three amino acid residues to be candidates to play a role in the difference in flecainide sensitivity between the sensitive subunits Kv3.1 and Kv4.2 and the insensitive subunits Kv1.4 and Kv1.5. We first used site-directed mutagenesis to alter each of these amino acids in Kv3.1 to those in Kv1.5, and to alter the amino acids in Kv1.5 to those in Kv3.1. Figure 6A illustrates the effects of several flecainide concentrations on current at +30 mV This article has not been copyedited and formatted. The final version may differ from this version. isoleucine/leucine mutants transformed the flecainide-sensitivity phenotype of each subunit to resemble that of its opposite WT counterpart. Table 2 shows the rate constants for leucine/isoleucine mutants compared to WTs, and indicate that like the WT channels, the main differences among the mutants was in the k on , suggesting that the differences in drug sensitivity were due to differences in drug access to the channel rather than stability of the drug-receptor complex.
This article has not been copyedited and formatted. The final version may differ from this version. Table 3 , despite the substantial changes in flecainide-sensitivity caused by the mutations, they did not affect the primary biophysical properties of the channels. Figure   7B shows the full concentration-response relations for the WT subunits and the isoleucine/leucine mutants at +30 mV. The mutations clearly reversed the flecainide-sensitivity differences, with curves for each point-mutated subunit superimposing on the curve of the opposite WT subunit. 
Effects of Corresponding Mutations in

Discussion
In this study, we have evaluated the basis for pharmacological sensitivity differences among four voltage-dependent K + -channel subunit channels. We find that a single, relatively conservative amino acid difference in S6 accounts for the variations in flecainide sensitivity.
Comparison with Previous Studies of Molecular Determinants of Cardiac Ion-Channel
Block. Replacing a leucine with an isoleucine in corresponding positions of the S6 transmembrane domain conferred to the flecainide-sensitive channels Kv3.1 and Kv4.2 a flecainide affinity like that of the insensitive subunits Kv1.4 and Kv1.5. Mutating the equivalent isoleucine in Kv1.4 and Kv1.5 to a leucine conferred strongly-increased sensitivity similar to that of Kv3.1 and Kv4.2. These subunits possess highly-conserved S5, pore and S6 segments.
Several previous studies have examined molecular motifs in these subunits that determine antiarrhythmic drug binding (Caballero et al, 2002; Decher et al, 2004; Franqueza et al, 1997; Yeola et al, 1996) . Yeola et al. (1996) were the first to examine the determinants of quinidine binding in Kv1.5. They noted that residues in the S6 segment, specifically T507 and V514, are significant determinants of quinidine block. Franqueza et al. (1997) showed that mutations at T507, L510 and V514 abolish stereoselectivity of bupivacaine block of Kv1.5. Caballero et al. study, slightly but significantly decreased sensitivity to S0100176. The authors concluded that specific S6 and pore helix residues facing the inner cavity form a binding pocket for S0100176.
There is also evidence for a role of S6 residues in determining drug block of Kv1.4 channels.
Substitutions at T529 alter sensitivity to quinidine and 4-aminopyridine (4AP), with a phenylalanine substitution in particular strongly reducing the affinity for quinidine (Zhang et al., 1998) . Model of Kv3.1 Channel Pore. We used molecular modeling to evaluate the position of the critical leucine/isoleucine amino-acid residue in relation to key structural components of Kv3.1.
The results of structural modeling (according to the approach described in the "Materials and L422 is located directly above the highly-conserved G424 residue that is generally considered to act as a gating hinge. This residue bends the inner helix by approximately 30 degrees in the crystal structure of MthK and is believed to provide part of the S6 segment flexibility required for Kv channel opening. It is thus possible that the L422I mutation alters the flexibility of the G424 region, thus modulating the rate at which flecainide has access to the channel inner cavity.
Figure 8 also includes the position of the hydrophilic L401 (green) and I389 (blue) residues, mutation of which failed to alter flecainide sensitivity of Kv3.1. The I389 residue is predicted to be located in the N-terminal end of the channel pore helix (blue) whereas the L401 residue is seen as part of the selectivity filter. Because I389 is more exposed to the external than internal medium, mutating this residue is not expected to affect the structure of the channel central cavity.
This article has not been copyedited and formatted. The final version may differ from this version. However, according to the proposed model, the leucine at position 401 could indirectly modify the position of the cavity-lining T400 residue and thus affect flecainide binding. In fact, residues at positions equivalent to T400 have been implicated in drug binding (see for instance Wulff et al., 2001 ). However, mutation of L401 is not likely to result in a significant change in the T400 orientation due to the high rigidity of the filter region.
The predicted positions of the I389, L401, L422 and V425 residues depend on the validity of our homology-based models. In this regard, it should be pointed out that the structural features of the L401, L422 and V425 residues are conserved whether Kv3.1 is modeled with MthK Atrial fibrillation is the most common clinical arrhythmia and its treatment remains suboptimal (Nattel et al., 2002) . Because of its atrial-selective localization, Kv1.5-based human I Kur has been suggested to be a potentially-interesting target for new antiarrhythmic drug development (Wang et al., 1993) . The present study was designed to shed light on the molecular determinant of reported differences seen between sensitive and insensitive subunits. The identification of a key amino-acid determinant is an important step in this direction. A better understanding of the molecular determinants of the drug-sensitivity of Kv1.5 and related channels may help in the rational design of new antiarrhythmic compounds.
Potential Limitations. The objective of this study was to determine the molecular basis for the differences in flecainide sensitivity among four subunits involved in forming native K + -channels for which discrepancies in sensitivity have been noted and studied previously. We did not set out to establish the details of the molecular determinants of the drug-binding site for each individual subunit. Although the latter issue is of great interest, it goes well beyond the scope of the present study. The S6+C-terminal chimeras containing the S6+C-terminal of Kv3.1 or Kv1.5 moved the flecainide sensitivity towards that of the subunit composition of the S6+C-terminal end. However, despite the fact that the S6+C-terminal contained the leucine/isoleucine moiety conferring flecainide sensitivity/insensitivity respectively in the respective wild types or point mutations, the changes in drug sensitivity were less with the chimeras than for the point mutations. This observation suggests that other molecular determinants in S6 and/or the Cterminus influence drug sensitivity in the chimeras, and can partly offset the effects of the leucine/isoleucine moiety.
This article has not been copyedited and formatted. The final version may differ from this version. The channel-blocking concentrations in this study are higher than those produced therapeutically, as well as values published in studies analyzing the effects of flecainide on I Kur.d in isolated atrial cells and in vivo models of AF (Yue et al., 2000b; Wang et al., 1992) . This discrepancy is likely due to the well-recognized lesser sensitivity to blocking drugs of channels expressed in Xenopus oocytes compared to mammalian cells (Weerapura et al, 2002) .
Nevertheless, the mechanisms of channel block in Xenopus oocytes are believed to be similar to those in other systems and Xenopus oocytes are widely used as an expression system for the analysis of structural motifs for channel block (Decher et al., 2004; Dibb et al., 2003; Perry et al., 2004; Wang et al., 2003) .
We used molecular modeling to evaluate the position of the critical leucine/isoleucine amino acid in relationship to key structural components of Kv3.1. We recognize that this modeling does not clarify the details of flecainide binding. As mentioned above, a full evaluation of the molecular structure of the drug-binding site goes beyond the scope of this study. In particular, further work is needed to delineate the amino acids that form the binding site and the mechanism of their interaction with the critical leucine/isoleucine residue that we identified.
Nevertheless, we feel that it is important to note the position of the leucine/isoleucine amino acid site in order to begin to assess potential mechanisms of its involvement. Further work will clearly be needed to reveal more of the details of flecainide's interactions with channels composed of Kv4.2, Kv3.1, Kv1.4 and Kv1.5 subunits. (Kv3.1/1.5C-term=chimera formed by substituting Kv1.5 C-terminal into Kv3.1; Kv1.5/3.1C-term=chimera formed by substituting Kv3.1 C-terminal into Kv1.5). This article has not been copyedited and formatted. The final version may differ from this version. TOP
